• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

APOL1 介导的单价阳离子转运有助于 APOL1 介导的肾脏病中的足细胞病变。

APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.

机构信息

Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University School of Medicine, Durham, North Carolina, USA.

Duke University School of Medicine, Department of Medicine, Division of Nephrology, Durham, North Carolina, USA.

出版信息

J Clin Invest. 2024 Jan 16;134(5):e172262. doi: 10.1172/JCI172262.

DOI:10.1172/JCI172262
PMID:38227370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10904047/
Abstract

Two coding variants of apolipoprotein L1 (APOL1), called G1 and G2, explain much of the excess risk of kidney disease in African Americans. While various cytotoxic phenotypes have been reported in experimental models, the proximal mechanism by which G1 and G2 cause kidney disease is poorly understood. Here, we leveraged 3 experimental models and a recently reported small molecule blocker of APOL1 protein, VX-147, to identify the upstream mechanism of G1-induced cytotoxicity. In HEK293 cells, we demonstrated that G1-mediated Na+ import/K+ efflux triggered activation of GPCR/IP3-mediated calcium release from the ER, impaired mitochondrial ATP production, and impaired translation, which were all reversed by VX-147. In human urine-derived podocyte-like epithelial cells (HUPECs), we demonstrated that G1 caused cytotoxicity that was again reversible by VX-147. Finally, in podocytes isolated from APOL1 G1 transgenic mice, we showed that IFN-γ-mediated induction of G1 caused K+ efflux, activation of GPCR/IP3 signaling, and inhibition of translation, podocyte injury, and proteinuria, all reversed by VX-147. Together, these results establish APOL1-mediated Na+/K+ transport as the proximal driver of APOL1-mediated kidney disease.

摘要

载脂蛋白 L1(APOL1)的两种编码变异体,称为 G1 和 G2,解释了非裔美国人肾病风险增加的很大一部分原因。虽然在实验模型中已经报道了各种细胞毒性表型,但 G1 和 G2 导致肾病的近端机制仍不清楚。在这里,我们利用 3 种实验模型和最近报道的一种 APOL1 蛋白小分子抑制剂 VX-147,来确定 G1 诱导的细胞毒性的上游机制。在 HEK293 细胞中,我们证明 G1 介导的 Na+内流/K+外流触发了 GPCR/IP3 介导的内质网钙释放的激活,损害了线粒体 ATP 的产生,并损害了翻译,这些都可以被 VX-147 逆转。在人尿源性足细胞样上皮细胞(HUPECs)中,我们证明 G1 导致了细胞毒性,再次可以被 VX-147 逆转。最后,在从 APOL1 G1 转基因小鼠分离的足细胞中,我们表明 IFN-γ 介导的 G1 诱导导致 K+外流、GPCR/IP3 信号的激活和翻译的抑制、足细胞损伤和蛋白尿,所有这些都可以被 VX-147 逆转。总之,这些结果确立了 APOL1 介导的 Na+/K+转运是 APOL1 介导的肾病的近端驱动因素。

相似文献

1
APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.APOL1 介导的单价阳离子转运有助于 APOL1 介导的肾脏病中的足细胞病变。
J Clin Invest. 2024 Jan 16;134(5):e172262. doi: 10.1172/JCI172262.
2
APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice.APOL1 肾风险变异体促进 APOL1 转基因小鼠组织和培养巨噬细胞中的胆固醇积累。
PLoS One. 2019 Apr 18;14(4):e0211559. doi: 10.1371/journal.pone.0211559. eCollection 2019.
3
Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.招募载脂蛋白 L1 肾病风险变异体到脂滴可减轻细胞毒性。
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3712-3721. doi: 10.1073/pnas.1820414116. Epub 2019 Feb 7.
4
Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression.载脂蛋白 L1 (APOL1) 肾脏风险变异介导的足细胞细胞毒性取决于非洲单倍型和表面表达。
Sci Rep. 2024 Feb 14;14(1):3765. doi: 10.1038/s41598-024-53298-4.
5
Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.载脂蛋白 L1 (APOL1) 在 HEK-293 细胞和人足细胞中的阳离子电流。
Pflugers Arch. 2023 Mar;475(3):323-341. doi: 10.1007/s00424-022-02767-8. Epub 2022 Nov 30.
6
APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.APOL1肾病风险变异体通过消耗细胞内钾离子和诱导应激激活蛋白激酶而导致细胞毒性。
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):830-7. doi: 10.1073/pnas.1522913113. Epub 2015 Dec 23.
7
Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.APOL1 高风险变异体 G1 和 G2 介导的肾脏疾病对血管紧张素转换酶抑制的不同敏感性。
Kidney Int. 2024 Dec;106(6):1072-1085. doi: 10.1016/j.kint.2024.07.026. Epub 2024 Aug 23.
8
APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.APOL1 风险变异通过增强内质网应激导致足细胞损伤。
Biosci Rep. 2018 Aug 29;38(4). doi: 10.1042/BSR20171713. Print 2018 Aug 31.
9
APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.APOL1 风险变异影响局灶节段性肾小球硬化症的足细胞脂质平衡和能量产生。
Hum Mol Genet. 2021 Apr 26;30(3-4):182-197. doi: 10.1093/hmg/ddab022.
10
Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.APOL1BAC 转基因小鼠模型中的隐性、功能获得毒性类似于人类的 APOL1 肾脏疾病。
Dis Model Mech. 2021 Aug 1;14(8). doi: 10.1242/dmm.048952. Epub 2021 Aug 5.

引用本文的文献

1
Apolipoprotein L1 (APOL1): Consideration of Molecular Evolution, Interaction with APOL3, and Impact of Splice Isoforms Advances Understanding of Cellular and Molecular Mechanisms of Cell Injury.载脂蛋白L1(APOL1):对分子进化、与APOL3相互作用以及剪接异构体影响的思考推动了对细胞损伤的细胞和分子机制的理解。
Cells. 2025 Jul 2;14(13):1011. doi: 10.3390/cells14131011.
2
A Cell Biologist's View on APOL1: What We Know and What We Still Need to Address.一位细胞生物学家对载脂蛋白L1(APOL1)的看法:我们所知道的以及仍需解决的问题。
Cells. 2025 Jun 24;14(13):960. doi: 10.3390/cells14130960.
3
G1 and G2 ApolipoproteinL1 modulate macrophage inflammation and lipid accumulation through the polyamine pathway.

本文引用的文献

1
Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease.APOL1 p.N264K 变异对 G2 相关局灶节段性肾小球硬化和肾脏疾病具有强大的保护作用。
Nat Commun. 2023 Nov 30;14(1):7836. doi: 10.1038/s41467-023-43020-9.
2
Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease.APOL1 孔形成功能的遗传抑制可预防 APOL1 介导的肾脏疾病。
J Am Soc Nephrol. 2023 Nov 1;34(11):1889-1899. doi: 10.1681/ASN.0000000000000219. Epub 2023 Oct 6.
3
No NLRP3 inflammasome activity in kidney epithelial cells, not even when the NLRP3-A350V Muckle-Wells variant is expressed in podocytes of diabetic mice.
G1和G2载脂蛋白L1通过多胺途径调节巨噬细胞炎症和脂质积累。
bioRxiv. 2025 Jun 8:2025.06.06.658371. doi: 10.1101/2025.06.06.658371.
4
The mislaid clue to APOL1 kidney disease prevention in blacks.黑人中预防载脂蛋白L1肾病丢失的线索。
J Hum Hypertens. 2025 Jun;39(6):389-391. doi: 10.1038/s41371-025-01024-6. Epub 2025 May 7.
5
Genomewide Screen Identifies Peroxisomal Role in APOL1 Podocytopathy.全基因组筛查确定过氧化物酶体在载脂蛋白L1足细胞病中的作用。
medRxiv. 2025 Feb 18:2025.02.15.25322241. doi: 10.1101/2025.02.15.25322241.
6
Advances in kidney disease: pathogenesis and therapeutic targets.肾病进展:发病机制与治疗靶点
Front Med (Lausanne). 2025 Feb 14;12:1526090. doi: 10.3389/fmed.2025.1526090. eCollection 2025.
7
Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities.靶向肾小球肾病中的I型干扰素通路:原理与治疗机会
Kidney Int Rep. 2024 Oct 21;10(1):29-39. doi: 10.1016/j.ekir.2024.10.013. eCollection 2025 Jan.
8
Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease.小分子载脂蛋白L1(APOL1)抑制剂作为治疗APOL1介导的肾脏疾病的精准药物方法。
Nat Commun. 2025 Jan 2;16(1):167. doi: 10.1038/s41467-024-55408-2.
9
The APOL1 p.N264K variant is co-inherited with the G2 kidney disease risk variant through a proximity recombination event.APOL1 p.N264K变异体通过邻近重组事件与G2型肾病风险变异体共同遗传。
G3 (Bethesda). 2025 Feb 5;15(2). doi: 10.1093/g3journal/jkae290.
10
Mechanistic Insights Into Redox Damage of the Podocyte in Hypertension.高血压中足细胞氧化还原损伤的机制性见解
Hypertension. 2025 Jan;82(1):14-25. doi: 10.1161/HYPERTENSIONAHA.124.22068. Epub 2024 Nov 13.
在肾脏上皮细胞中没有 NLRP3 炎性小体的活性,即使在糖尿病小鼠的足细胞中表达 NLRP3-A350V 突变体也是如此。
Front Immunol. 2023 Aug 23;14:1230050. doi: 10.3389/fimmu.2023.1230050. eCollection 2023.
4
Pyruvate-supported flux through medium-chain ketothiolase promotes mitochondrial lipid tolerance in cardiac and skeletal muscles.丙酮酸支持的中链酮硫解酶通量促进心肌和骨骼肌的线粒体脂质耐受性。
Cell Metab. 2023 Jun 6;35(6):1038-1056.e8. doi: 10.1016/j.cmet.2023.03.016. Epub 2023 Apr 14.
5
Inaxaplin for Proteinuric Kidney Disease in Persons with Two Variants.Inaxaplin 用于伴有两种变异的蛋白尿性肾病患者。
N Engl J Med. 2023 Mar 16;388(11):969-979. doi: 10.1056/NEJMoa2202396.
6
Transcriptomic Analysis of Human Podocytes : Effects of Differentiation and Genotype.人足细胞的转录组分析:分化和基因型的影响
Kidney Int Rep. 2022 Oct 17;8(1):164-178. doi: 10.1016/j.ekir.2022.10.011. eCollection 2023 Jan.
7
variant-expressing endothelial cells exhibit autophagic dysfunction and mitochondrial stress.表达变体的内皮细胞表现出自噬功能障碍和线粒体应激。
Front Genet. 2022 Sep 27;13:769936. doi: 10.3389/fgene.2022.769936. eCollection 2022.
8
Risk Variants Impair Multiple Mitochondrial Pathways in a Metabolomics Analysis.风险变异体在代谢组学分析中损害多个线粒体途径。
Kidney360. 2020 Sep 30;1(12):1353-1362. doi: 10.34067/KID.0003592020. eCollection 2020 Dec 31.
9
Moving Toward a Common Pathogenic Mechanism and Therapeutic Targets for APOL1 Nephropathies.迈向APOL1肾病的共同致病机制和治疗靶点
Am J Kidney Dis. 2022 Jun;79(6):901-903. doi: 10.1053/j.ajkd.2022.02.011. Epub 2022 Feb 28.
10
The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.载脂蛋白 L1 肾病的演变故事:开端的结束。
Nat Rev Nephrol. 2022 May;18(5):307-320. doi: 10.1038/s41581-022-00538-3. Epub 2022 Feb 25.